Research Topics
Species | A ArgirisSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Induction chemotherapy for head and neck cancer: will history repeat itself?Athanassios Argiris
Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
J Natl Compr Canc Netw 3:393-403. 2005..A number of randomized trials are planned or currently ongoing to investigate concurrent chemoradiotherapy with or without induction. These trials are anticipated to redefine the role of induction chemotherapy for head and neck cancer...- Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancerAthanassios Argiris
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
Laryngoscope 118:444-9. 2008..The role of postoperative radiotherapy and carboplatin in squamous cell carcinoma of the head and neck (SCCHN) has not been established... 
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology GroupAthanassios Argiris
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Cancer 115:4504-13. 2009..Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN...- A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancerAthanassios Argiris
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
Invest New Drugs 26:183-8. 2008..The combination of doxorubicin and interferon alpha is supported by preclinical data. We sought to evaluate the efficacy of this combination in patients with advanced thyroid cancer... - Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole storyAthanassios Argiris
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
J Thorac Oncol 1:52-60. 2006..The study of molecular markers may identify the subset of patients who are the most appropriate to treat with these agents... - A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancerAthanassios Argiris
Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
Cancer Biol Ther 5:766-70. 2006..Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts... 
Empowering induction therapy for locally advanced head and neck cancerA Argiris
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
Ann Oncol 22:773-81. 2011....- Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancerAthanassios Argiris
University of Pittsburgh Medical Center Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
J Clin Oncol 28:5294-300. 2010..We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC)... - A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
Cancer 117:3374-82. 2011..Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin... - Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancerAthanassios Argiris
Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
J Clin Oncol 29:1140-5. 2011..We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN)... - Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancerA Argiris
University of Pittsburgh Cancer Institute, Division of Hematology Oncology, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
Ann Oncol 22:2482-8. 2011..We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer... - A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancerA Argiris
Division of Hematology Oncology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Lung Cancer 45:243-53. 2004.... - Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levelsJ K Salama
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
Ann Oncol 19:1787-94. 2008..Additionally, we systematically lowered radiotherapy (RT) doses attempting to maintain LRC while decreasing toxicity... - Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapyV A Passero
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh and Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, SA
Ann Oncol 21:2278-83. 2010..F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome... - Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancersA S Gokhale
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Ann Oncol 21:145-51. 2010..Patients treated with chemoradiotherapy (CRT) for head and neck cancers often require feeding tubes (FTs) due to toxicity. We sought to identify factors associated with a prolonged FT requirement... - Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancerDaniel J Haraf
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637 1470, USA
Clin Cancer Res 9:5936-43. 2003..In an attempt to decrease toxicity without compromising local control, a second cohort of patients was treated with a lower dose of radiation to sites of potential microscopic disease... - Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancerS S Agarwala
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, PA 15232, USA
Ann Oncol 18:1224-9. 2007..Our goal was to evaluate long-term efficacy outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) treated with carboplatin, paclitaxel (Taxol) and radiotherapy... - Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
Cancer Epidemiol Biomarkers Prev 19:358-65. 2010.... - Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancerAthanassios Argiris
Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
Lung Cancer 43:317-22. 2004..To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line compassionate use therapy for advanced non-small-cell Lung cancer (NSCLC)... - Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancerAthanassios Argiris
The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
Head Neck 26:447-55. 2004..The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck... - The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler
Rush University Medical Center, Chicago, Illinois 60612, USA
Clin Cancer Res 14:2088-94. 2008..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC... - Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primaryA Argiris
Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Ann Oncol 14:1306-11. 2003..Our aim was to explore the use of concurrent chemoradiotherapy in the management of patients with squamous cell carcinoma of the head and neck from an occult primary (HNCOP)... - Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failureAthanassios Argiris
Division of Hematology Oncology, Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Oncologist 8:350-60. 2003..The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease... - Therapies directed against epidermal growth factor receptor in aerodigestive carcinomasMichalis V Karamouzis
Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
JAMA 298:70-82. 2007..Given the biological importance of epidermal growth factor receptor (EGFR) in cancer development and progression, EGFR inhibitors have emerged as promising novel therapies... - Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)Victoria Kut
Department of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL, USA
Am J Clin Oncol 30:45-50. 2007..18F]Fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan is widely used for the staging evaluation of nonsmall cell lung cancer, however, its use in small cell lung cancer (SCLC) remains investigational... - Induction chemotherapy for resectable non-small-cell lung cancerJyoti D Patel
Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
Oncology (Williston Park) 18:1591-602; discussion 1602-3, 1606, 1611-2. 2004..Randomized trials are under way to better define the role of induction therapy in the multimodality treatment of NSCLC... - Revisiting induction chemotherapy for head and neck cancerAthanassios Argiris
Division of Hematology Oncology, Northwestern University Chicago, Illinois 60611, USA
Oncology (Williston Park) 19:759-70. 2005..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents... - PET scan assessment of chemotherapy response in metastatic paragangliomaAthanassios Argiris
Division of Hematology-Oncology, The Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
Am J Clin Oncol 26:563-6. 2003..It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas... - Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neckMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
Clin Cancer Res 10:4922-32. 2004..Refinements in radiotherapy, including intensity-modulated radiation therapy, may improve the tolerance for this regimen... - Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphomaA Argiris
Northwestern University Medical School, Division of Hematology-Oncology, and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Invest New Drugs 19:321-6. 2001.... - Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agentsA Argiris
Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
Cancer J 7:228-35. 2001..These data support further evaluation of the newer chemotherapeutic drugs, and especially the camptothecins (irinotecan and topotecan) and the taxanes (paclitaxel and docetaxel), in the initial treatment of SCLC... - Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 61:1096-106. 2005..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck... - Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at Narissa J Nonzee
Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University, Chicago, Illinois 60611, USA
Cancer 113:1446-52. 2008..Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications... - Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanismsStephen Y Lai
Departments of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
J Clin Oncol 27:1235-42. 2009..A phase I clinical trial was conducted to evaluate the safety and biologic effects of EGFR AS... - Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CTJayakar V Nayak
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Laryngoscope 117:2129-34. 2007..To determine whether combined positron emission tomography and computed tomography (PET-CT) may be of value in deferring planned neck dissections for patients with advanced head and neck squamous cell carcinoma (HNSCC)... - Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trialDwight E Heron
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
Int J Radiat Oncol Biol Phys 75:1493-500. 2009..To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN)... - Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancerAthanassios Argiris
Division of Hematology-Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
Invest New Drugs 24:203-12. 2006..Diarrhea was the most common toxicity. Antitumor activity was promising. The alteration of irinotecan pharmacokinetic parameters observed may not be clinically relevant... - Revisiting induction chemotherapy for head and neck cancer. References and reviewsAthanassios Argiris
Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
Oncology (Williston Park) 19:932-4, 939; discussion 939-45. 2005..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents... - A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancerAhmad A Tarhini
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
Hum Gene Ther 22:336-42. 2011..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg... - Staging and clinical prognostic factors for small-cell lung cancerA Argiris
Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Cancer J 7:437-47. 2001..Identification of risk factors for treatment-related mortality is important for the management of patients with SCLC... - Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapyAthanassios Argiris
Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
J Clin Oncol 22:262-8. 2004..To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy... - Pemetrexed: a novel antifolate agent enters clinical practiceVictoria Kut
Department of Medicine, Division of Hematology/Oncology, The Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
Expert Rev Anticancer Ther 4:511-22. 2004..Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer... - Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we goJyoti D Patel
Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Crit Rev Oncol Hematol 50:175-86. 2004..The goal of ongoing and future investigation is to identify which patients may benefit from this new therapeutic approach... - Update on the role of EGFR inhibitors in cancer therapeuticsMichalis V Karamouzis
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Cancer Treat Res 135:257-75. 2007 - Head and neck cancerAthanassios Argiris
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
Lancet 371:1695-709. 2008..We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck... - Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neckA Argiris
Department of Medicine, Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Ann Oncol 24:220-5. 2013.... - Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical reviewBharat B Mittal
Department of Radiology, Section of Radiation Oncology, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Int J Radiat Oncol Biol Phys 57:1219-30. 2003 - Update on chemoradiotherapy for head and neck cancerAthanassios Argiris
Division of Hematology Oncology, Northwestern University Medical School and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Curr Opin Oncol 14:323-9. 2002..Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy... - Esthesioneuroblastoma: the Northwestern University experienceAthanassios Argiris
Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Laryngoscope 113:155-60. 2003..To review our experience with esthesioneuroblastoma, a rare malignancy of the head and neck... - Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neckAthanassios Argiris
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
Cancer 101:2222-9. 2004.... - The impact of health insurance status on the survival of patients with head and neck cancerJoseph Kwok
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
Cancer 116:476-85. 2010..The main outcome measures were overall survival and relapse-free survival... - Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experienceBrian T McLaughlin
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
Laryngoscope 120:71-5. 2010..Mucositis and dysphagia are common complications of chemoradiotherapy (CRT) for head and neck cancer that may necessitate nutritional support with a gastrostomy tube (G-tube)... - Epidemiology, staging, and screening of head and neck cancerAthanassios Argiris
Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
Cancer Treat Res 114:15-60. 2003 - Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapyAthanassios Argiris
The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Clin Cancer Res 10:1956-62. 2004.... - Clinical applications of gene therapy in head and neck cancerMichalis V Karamouzis
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Curr Gene Ther 7:446-57. 2007..Systemic delivery of gene therapy may be also possible, albeit with several limitations. In this review we will discuss the rationale, delivery methods, and accumulated clinical data with cancer gene therapy in SCCHN... - Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemiaAdi Gidron
Division of Hematology-Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
Am J Clin Oncol 29:213-4. 2006 - Planned post-chemoradiation neck dissection: significance of radiation doseKerstin M Stenson
Department of Surgery, Section of Otolaryngology Head and Neck Surgery, University of Chicago, Illinois 60637, USA
Laryngoscope 116:33-6. 2006..We report the pathologic data on patients undergoing neck dissection (ND) after induction chemotherapy followed by concomitant chemoradiotherapy (IC-CRT) in three similar protocols utilizing decreasing doses of radiation therapy... - Targeting growth factors and angiogenesis; using small molecules in malignancyHarold J Wanebo
Department of Surgery, Division Surgical Oncology, Roger Williams Medical Center, Providence, RI, USA
Cancer Metastasis Rev 25:279-92. 2006.... - Can current treatments for advanced non-small-cell lung cancer be improved?Athanassios Argiris
JAMA 292:499-500. 2004 - Emerging molecular targeted therapies in squamous cell carcinoma of the head and neckJill Gilbert
Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Clin Adv Hematol Oncol 4:611-9. 2006..The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN... - A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scoresSusan Yount
Center on Outcomes, Research and Education CORE, Evanston Northwestern Healthcare, Evanston, IL 60201, USA
Qual Life Res 16:1615-26. 2007..To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI)... - Synergistic interactions between tamoxifen and trastuzumab (Herceptin)Athanassios Argiris
Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut 06510, USA
Clin Cancer Res 10:1409-20. 2004..In vitro, the individual drugs or combination produces a cytostatic effect. These results suggest that combined inhibition of ER and HER-2/neu signaling may represent a powerful approach to the treatment of breast cancer... - Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancerEric Bleickardt
Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Biol Ther 1:646-51. 2002..Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers... - Progress in the therapy of small cell lung cancerMiklos Simon
Section of Medical Oncology, Yale University School of Medicine, P.O. Box 208032, 333 Cedar Str #287 NSB, New Haven, CT 06520-8032, USA
Crit Rev Oncol Hematol 49:119-33. 2004..Novel molecular targeted therapies are among the strategies currently being investigated in SCLC...